Business description
Viking Therapeutics, Inc. is a biopharmaceutical company developing therapies for metabolic and endocrine disorders. Its lead candidate, VK2809, is in Phase IIb trials for non-alcoholic steatohepatitis. The company also focuses on treatments for diabetes and X-linked adrenoleukodystrophy.
Management board & Supervisory board
| CEO |
| Brian Lian |
| Management board |
| Greg Zante, Marianne Mancini, Geoffrey Barker, Michael Morneau |
| Supervisory board |
| Lawson Macartney, Matthew W. Foehr, Kathy Rouan, Charles A. Rowland Jr., Matthew Singleton |
Company data
| Name: |
Viking Therapeutics Inc. |
| Address: |
9920 Pacific Heights Blvd, Suite 350,San Diego, CA 92121 |
| Phone: |
+1-858-704-4660 |
| Fax: |
- |
| E-mail: |
-
|
| Internet: |
https://vikingtherapeutics.com/ |
| Industry: |
Biotechnology |
| Sector: |
Biotechnology |
| Sub sector: |
Biotechnology |
| End of financial year: |
12-31 |
| Free Float: |
92.05% |
| IPO date: |
- |
